Adagene Inc.
muzastotug
microsatellite stable colorectal cancer (MSS CRC)
Countdown
178days
Phase 2 readout · ~ Jan 1, 2027 estimated
What's at stake
Phase 2 trial results for muzastotug in microsatellite stable colorectal cancer (MSS CRC) are due ~ Jan 1, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“results are expected in the first half of 2027.”